33 results about "Transmembrane peptide" patented technology

The invention discloses a ternary gene delivery system based on cell-penetrating peptide and applications of the ternary gene delivery system. The ternary gene delivery system based on the cell-penetrating peptide is prepared by adopting the following method: multifunctional polypeptide REDV-G-TAT-G-NLG-C is connected to eight active sites of octa ammonium POSS (polyhedral oligomeric silsesquioxane) through orthopyridyl disulfide-PEG-NHS ester, and thus a star polymer is formed; the star polymer with positive charges and a gene with negative electricity are bonded through electrostatic interaction, and thus a binary gene delivery system with negative electricity on the surface is formed; a polypeptide sequence rich in histidine and the binary gene delivery system are bonded through electrostatic interaction, and thus the ternary gene delivery system is formed. The ternary gene delivery system based on cell-penetrating peptide provided by the invention has targeting ability for endothelial cells, and has the functions of cell-penetrating peptide, histidine and nuclear localization signals, so that carried genes can efficiently enter cells, the escape from endosome is effectively carried out, the entering of the genes into the cell nucleus is realized, and finally, the gene delivery effect is greatly improved.

The present invention provides a tandem penetrating peptide modified tumor targeting and tumor penetrating nano drug delivery system that simultaneously recognizes integrin receptors and transmembrane protein receptors. The tandem penetrating peptide is mainly a DGR polypeptide. The fragment is formed by covalently connecting to the C-terminus of the penetrating peptide polyarginine, and the polypeptide can not only selectively recognize receptors highly expressed on the surface of two types of tumor cells, but also efficiently mediate into cells. The nano-drug delivery system is mainly composed of nano-carriers, drugs and lipid-polyethylene glycol-tandem transmembrane peptide ligand chimeras, and is a potential tumor-targeted therapy carrier.

The invention provides a high-flux prey antagonist screening method based on membrane binding protein and fluorescence complementation, relates to the field of gene engineering, and concretely discloses a novel method for screening a receptor antagonist and application thereof. According to the method, a ligand existing outside a cell and a receptor are expressed to the cytomembrane through a signal peptide fusion expression strategy; a ligand structural domain generating mutual action with the receptor is enabled to be remained at the outer side of the cytomembrane; the ligand is coupled with intracellular effect proteins through transmembrane peptide; the ligand and the receptor take mutual effects at the outer side of the cytomembrane, or the effect proteins coupled in the cells are antagonized; and the effect is converted into a macroscopical biological effect, so that the method is provided for the screening of the secretion type ligand and receptor antagonists.

The invention belongs to the technical field of bioengineering, and in particular relates to an EGF-like protein, a construction method thereof, a chimeric protein, a preparation method and application thereof. The invention provides an EGF-like protein, and the EGF-like protein is EGF‑CTA 2 ‑TAT protein, EGF‑CTA 2 The nucleotide sequence of the -TAT protein is shown in SEQ ID NO:1. EGF-CTA of the present invention 2 ‑TAT protein is chimerized with EGF protein with repair function, membrane-penetrating peptide TAT to assist transdermal absorption, and cholera toxin A2 subunit (CTA) with the ability to penetrate the cell membrane 2 ), the cell activity test results showed that EGF‑CTA 2 ‑TAT protein has obvious growth-promoting effect on BALB / c 3T3 cell line and has biological activity.

The invention discloses a transmembrane peptide-mediated antisense antibacterial agent which comprises popliteal lymph node assay (PLNA) 787; and the PLNA 787 is formed by connecting transmembrane peptide (KFF) 3K and LNA 787 by cysteine-(4-(N-maleimide methyl)-1- cyclohexidine actidione)-hexane and is prepared by a solid phase synthesis method. The transmembrane peptide-mediated antisense antibacterial agent takes bacteria curing gene as a target spot, has the advantages of being high in specificity, efficient, low in toxicity, safe and the like, has remarkable inhibition effect on the growth of drug-resistant bacteria, and especially has remarkable antagonism on the growth of methicillin-resistant staphylococcus aureus.

The invention discloses a fusion protein TAT (transactivator of transcription)-OCT4 (octamer-binding transcription factor 4), and a coding gene and application thereof. The fusion protein provided by the invention comprises a TAT transmembrane peptide and a cell reprogramming correlation factor combined with an amino end or carboxyl end of the TAT transmembrane peptide. After the fusion protein-TAT OCT4 is used for treating HAFs (human aortic fibroblasts), the proliferation of the fibroblasts is promoted, and the enhancement of the expression level of the cyclins in the fibroblasts is promoted. The TAT transmembrane peptide transported nuclei transcription factor protein can be used as a cell reprogramming method, and can have important application prospects in cell induction and clinic.

The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.